Early Molecular Response <= 1% Has Strong Prognostic Impact For Cml Patients That Switch To Second-Line Therapy With Bcr-Abl1 <= 10% And No Major Molecular Response
BRITISH JOURNAL OF HAEMATOLOGY（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined